UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 32

Sortiert nach

Impact of Early Consumption of High-Fat Diet on the Mesolimbic Dopaminergic System

eNeuro, 2017-05, Vol.4 (3), p.ENEURO.0120-17.2017-12

2017

Link zum Volltext

Verfügbarkeit prüfen

Brain metastases response to nivolumab in patients with renal cell carcinoma (RCC): Prospective analysis from the GETUG-AFU 26 (NIVOREN) trial

Annals of oncology, 2018-10, Vol.29, p.viii306-viii306

2018

Link zum Volltext

Verfügbarkeit prüfen

687P NIVOREN GETUG-AFU 26 translational study: Baseline peripheral cytokines predict survival in metastatic clear cell renal carcinoma (RCC) treated with nivolumab

Annals of oncology, 2021-09, Vol.32, p.S704-S705

2021

Link zum Volltext

Verfügbarkeit prüfen

Fresh blood Immune cell monitoring in patients treated with nivolumab in the GETUG-AFU26 NIVOREN study: Association with toxicity and treatment outcome

Annals of oncology, 2019-10, Vol.30, p.v394

2019

Link zum Volltext

Verfügbarkeit prüfen

972P - Fresh blood Immune cell monitoring in patients treated with nivolumab in the GETUG-AFU26 NIVOREN study: Association with toxicity and treatment outcome

Annals of oncology, 2019-10, Vol.30, p.v394-v394

2019

Link zum Volltext

Verfügbarkeit prüfen

697P Impact of β-blockers (BB) on outcomes of metastatic renal cell carcinoma (mRCC) patients treated with nivolumab (N)

Annals of oncology, 2021-09, Vol.32, p.S710-S710

2021

Link zum Volltext

Verfügbarkeit prüfen

657MO Antibiotic (ATB) therapy and outcome from nivolumab (N) in metastatic renal cell carcinoma (mRCC) patients (pts): Results of the GETUG-AFU 26 NIVOREN multicentric phase II study

Annals of oncology, 2021-09, Vol.32, p.S681-S681

2021

Link zum Volltext

Verfügbarkeit prüfen

689P Human leukocyte antigen (HLA) class I/II expression as a predictive biomarker for response to immune oncology (IO) therapy in metastatic clear-cell renal cell carcinoma (m-ccRCC)

Annals of oncology, 2021-09, Vol.32, p.S706-S706

2021

Link zum Volltext

Verfügbarkeit prüfen

Human leukocyte antigen (HLA) class I/II expression as a predictive biomarker for response to immune oncology (IO) therapy in metastatic clear-cell renal cell carcinoma (m-ccRCC)

Annals of oncology, 2021-09, Vol.32, p.S706-S706

2021

Link zum Volltext

Verfügbarkeit prüfen

700O Kidney ccRCC immune classification (KIC) enhances the predictive value of T effector (Teff) and angiogenesis (Angio) signatures in response to nivolumab (N)

Annals of oncology, 2020-09, Vol.31, p.S553-S553

2020

Link zum Volltext

Verfügbarkeit prüfen

Kidney ccRCC immune classification (KIC) enhances the predictive value of T effector (Teff) and angiogenesis (Angio) signatures in response to nivolumab (N)

Annals of oncology, 2020-09, Vol.31, p.S553-S553

2020

Link zum Volltext

Verfügbarkeit prüfen

Impact of corticosteroids on nivolumab activity in metastatic clear cell renal cell carcinoma

Annals of oncology, 2019-10, Vol.30, p.v391

2019

Link zum Volltext

Verfügbarkeit prüfen

966P - Impact of corticosteroids on nivolumab activity in metastatic clear cell renal cell carcinoma

Annals of oncology, 2019-10, Vol.30, p.v391-v391

2019

Link zum Volltext

Verfügbarkeit prüfen

184P Elevated baseline circulating IL-8 is associated with increased expression of the IMmotion myeloid gene signature (GS) in metastatic clear cell renal cell carcinoma (mRCC) patients (pts) treated with nivolumab (nivo) within the NIVOREN GETUG-AFU 26 study

Immuno-oncology technology, 2023-12, Vol.20, p.100643, Article 100643

2023

Link zum Volltext

Verfügbarkeit prüfen

972PFresh blood Immune cell monitoring in patients treated with nivolumab in the GETUG-AFU26 NIVOREN study: Association with toxicity and treatment outcome

Annals of oncology, 2019-10, Vol.30 (Supplement_5)

2019

Link zum Volltext

Verfügbarkeit prüfen

966PImpact of corticosteroids on nivolumab activity in metastatic clear cell renal cell carcinoma

Annals of oncology, 2019-10, Vol.30 (Supplement_5)

2019

Link zum Volltext

Verfügbarkeit prüfen

868PDBrain metastases response to nivolumab in patients with renal cell carcinoma (RCC): Prospective analysis from the GETUG-AFU 26 (NIVOREN) trial

Annals of oncology, 2018-10, Vol.29 (suppl_8)

2018

Link zum Volltext

Verfügbarkeit prüfen

909PDNIVOREN GETUG-AFU 26 translational study: CD8 infiltration and PD-L1 expression are associated with outcome in patients (pts) with metastatic clear cell renal cell carcinoma (mccRCC) treated with nivolumab (N)

Annals of oncology, 2019-10, Vol.30 (Supplement_5)

2019

Link zum Volltext

Verfügbarkeit prüfen

Comparison of cardiac output measured by oesophageal Doppler ultrasonography or pulse pressure contour wave analysis

British journal of anaesthesia : BJA, 2015-06, Vol.114 (6), p.893-900

2015

Link zum Volltext

Verfügbarkeit prüfen

Sound and light from fractures in scintillators

Physical review letters, 2013-10, Vol.111 (15), p.154301-154301, Article 154301

2013

Link zum Volltext

Verfügbarkeit prüfen

A multi-channel setup to study fractures in scintillators

Measurement science & technology, 2016-12, Vol.27 (12), p.125601

2016

Link zum Volltext

Verfügbarkeit prüfen

Thrombolytic Therapy with Streptokinase in Acute Ischemic Stroke

The New England journal of medicine, 1996-07, Vol.335 (3), p.145-150

1996

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 32

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(28)
Mit Volltextzugriff
(30)

Publikationsform

Artikel
(29)
Tagungsberichte
(3)

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Impact of Early Consumption of High-Fat Diet on the Mesolimbic Dopaminergic System

Brain metastases response to nivolumab in patients with renal cell carcinoma (RCC): Prospective analysis from the GETUG-AFU 26 (NIVOREN) trial

687P NIVOREN GETUG-AFU 26 translational study: Baseline peripheral cytokines predict survival in metastatic clear cell renal carcinoma (RCC) treated with nivolumab

1480P Baseline levels of proinflammatory cytokines according to body mass index (BMI) and BMI impact on clinical outcomes in metastatic renal cell carcinoma (mRCC) patients (pts) treated with nivolumab (NIVO) within the NIVOREN trial

Fresh blood Immune cell monitoring in patients treated with nivolumab in the GETUG-AFU26 NIVOREN study: Association with toxicity and treatment outcome

972P - Fresh blood Immune cell monitoring in patients treated with nivolumab in the GETUG-AFU26 NIVOREN study: Association with toxicity and treatment outcome

697P Impact of β-blockers (BB) on outcomes of metastatic renal cell carcinoma (mRCC) patients treated with nivolumab (N)

657MO Antibiotic (ATB) therapy and outcome from nivolumab (N) in metastatic renal cell carcinoma (mRCC) patients (pts): Results of the GETUG-AFU 26 NIVOREN multicentric phase II study

689P Human leukocyte antigen (HLA) class I/II expression as a predictive biomarker for response to immune oncology (IO) therapy in metastatic clear-cell renal cell carcinoma (m-ccRCC)

Human leukocyte antigen (HLA) class I/II expression as a predictive biomarker for response to immune oncology (IO) therapy in metastatic clear-cell renal cell carcinoma (m-ccRCC)

700O Kidney ccRCC immune classification (KIC) enhances the predictive value of T effector (Teff) and angiogenesis (Angio) signatures in response to nivolumab (N)

Kidney ccRCC immune classification (KIC) enhances the predictive value of T effector (Teff) and angiogenesis (Angio) signatures in response to nivolumab (N)

Impact of corticosteroids on nivolumab activity in metastatic clear cell renal cell carcinoma

966P - Impact of corticosteroids on nivolumab activity in metastatic clear cell renal cell carcinoma

NIVOREN GETUG-AFU 26 translational study: CD8 infiltration and PD-L1 expression are associated with outcome in patients (pts) with metastatic clear cell renal cell carcinoma (mccRCC) treated with nivolumab (N)

909PD - NIVOREN GETUG-AFU 26 translational study: CD8 infiltration and PD-L1 expression are associated with outcome in patients (pts) with metastatic clear cell renal cell carcinoma (mccRCC) treated with nivolumab (N)

184P Elevated baseline circulating IL-8 is associated with increased expression of the IMmotion myeloid gene signature (GS) in metastatic clear cell renal cell carcinoma (mRCC) patients (pts) treated with nivolumab (nivo) within the NIVOREN GETUG-AFU 26 study

972PFresh blood Immune cell monitoring in patients treated with nivolumab in the GETUG-AFU26 NIVOREN study: Association with toxicity and treatment outcome

966PImpact of corticosteroids on nivolumab activity in metastatic clear cell renal cell carcinoma

868PDBrain metastases response to nivolumab in patients with renal cell carcinoma (RCC): Prospective analysis from the GETUG-AFU 26 (NIVOREN) trial

909PDNIVOREN GETUG-AFU 26 translational study: CD8 infiltration and PD-L1 expression are associated with outcome in patients (pts) with metastatic clear cell renal cell carcinoma (mccRCC) treated with nivolumab (N)

Comparison of cardiac output measured by oesophageal Doppler ultrasonography or pulse pressure contour wave analysis

Sound and light from fractures in scintillators

A multi-channel setup to study fractures in scintillators

Thrombolytic Therapy with Streptokinase in Acute Ischemic Stroke

Suchergebnisse filtern